Guidelines for the treatment of invasive aspergillosis

Authors: Ráčil Zdenek 1;  Mayer Jiří 1;  Kocmanová Iva 2;  Haber Jan 3;  Mallátová Naďa 4;  Kouba Michal 5;  Sedláček Petr 6;  Faber Edgar 7;  Herold Ivan 8;  Múdry Peter 9;  Drgoňa Luboš 10;  Karas Michal 11;  Buchta Vladimír 12;  Vydra Jan 13;  Kolář Michal 14;  Trupl Jan 15;  Marešová Vilma 16;  Rozsypal Hanuš 16;  Nyč Otakar 17;  Cwiertka Karel 18
Authors‘ workplace: Interní hematoonkologická klinika, FN Brno 1;  Národný onkologický ústav, Bratislava, Slovensko 10;  Hematologicko-onkologické oddělení FN Plzeň 11;  Ústav klinické mikrobiologie FN Hradec Králové 12;  Oddělení klinické hematologie FNKV Praha 13;  KAR VFN, Praha 14;  Klinika laboratorní medicíny SYNLAB, s. r. o., Bratislava, Slovensko 15;  Infekční klinika FN Na Bulovce, Praha 16;  Ústav lékařské mikrobiologie FN Motol, Praha 17;  Onkologická klinika FN Olomouc 18;  Oddělení klinické mikrobiologie, FN Brno 2;  I. interní klinika – hematoonkologická VFN, Praha 3;  Laboratoř lékařské parazitologie a mykologie, Centrální laboratoře, Nemocnice České Budějovice, a. s. 4;  Ústav hematologie a krevní transfuze Praha 5;  Klinika dětské hematologie a onkologie FN Motol, Praha 6;  Hematoonkologická klinika FN Olomouc 7;  ARO, Klaudiánova nemocnice Mladá Boleslav 8;  Klinika dětské onkologie, FN Brno 9
Published in: Anest. intenziv. Med., 20, 2009, č. 1, s. 48-56
Category: The recommendations of professional societies


An increasing incidence of invasive aspergillosis is observed in most immunocompromised patients, and especially in patients with acute leukemia and following haematopoietic stem cell transplantation. In order to decrease mortality due to this infection, clinicians need to optimize their treatment choices.

The objective of these guidelines is to summarize the current evidence for the treatment of invasive aspergillosis. The recommendations have been developed by an expert panel following an evidence-based literature search with regard to current recommendations of the European Conference in Infections in Leukemia and Infectious Diseases Society of America.

Key words:
invasive aspergillosis – treatment guidelines – antimycotics


1. Ráčil, Z., Mayer, J. (eds) Invazivní aspergilóza: současné možnosti diagnostiky. Vnitř. Lék., 2007, 53, Suppl.

2. Herbrecht, R., Fluckiger, U., Gachot, B. et al. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. European Journal of Cancer Supplements. Guidelines from the First European Conference on Infections in Leukaemia: ECIL1, 2007, 5, p. 49–59.

3. Walsh, T. J., Anaissie, E. J., Denning, D. W. et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis., 2008, 46, p. 327–360.

4. Ascioglu, S., Rex, J. H., de Pauw, B. et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis., 2002, 34, p. 7–14.

5. Herbrecht, R., Denning, D. W., Patterson, T. F. et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med., 2002, 347, p. 408–415.

6. Chen, S. C., Sorrell, T. C. Antifungal agents. Med. J. Aust., 2007, 187, p. 404–409.

7. Ostrosky-Zeichner, L., Marr, K. A., Rex, J. H. et al. Amphotericin B: time for a new “gold standard“. Clin. Infect. Dis., 2003, 37, p. 415–425.

8. Ellis, M., Spence, D., de Pauw, B. et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin. Infect. Dis., 1998, 27, p. 1406–1412.

9. Cordonnier, C., Bresnik, M., Ebrahimi, R. Liposomal Amphotericin B (L-AMB) Efficacy in Invasive Filamentous Fungal Infections (IFI): Pooled Analysis. Program and abstracts of the 44th ICAAC October 30 – November 2, 2004, Abstract M-1022.

10. Cornely, O. A., Maertens, J., Bresnik, M. et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin. Infect. Dis., 2007, 44, p. 1289–1297.

11. Chandrasekar, P. H., Ito, J. I. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis., 2005, 40, Suppl 6, p. S392–400.

12. Bowden, R., Chandrasekar, P., White, M. H. et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis., 2002, 35, p. 359–366.

13. Denning, D. W., Lee, J. Y., Hostetler, J. S. et al. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am. J. Med., 1994, 97, p. 135–144.

14. Caillot, D., Bassaris, H., McGeer, A. et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin. Infect. Dis., 2001, 33, p. e83–90.

15. Prentice, A. G., Glasmacher, A. Making sense of itraconazole pharmacokinetics. J. Antimicrob. Chemother., 2005, 56, Suppl 1, p. i17–i22.

16. Viscoli, C., Herbrecht, R., Akan, H. Caspofungin (C) as first-line therapy of invasive aspergillosis (IA) in haematological patients (pts): a study of the EORTC Infectious Diseases Group. 3th Trends in Medical Mycology 2007: Abstract O.12.

17. Denning, D. W., Marr, K. A., Lau, W. M. et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J. Infect., 2006, 53, p. 337–349.

18. Kohno, S., Masaoka, T., Yamaguchi, H. et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand. J. Infect. Dis., 2004, 36, p. 372–379.

19. Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A. et al. Combination treatment of invasive fungal infections. Clin. Microbiol. Rev., 2005, 18, p. 163–194.

20. Kontoyiannis, D. P., Hachem, R., Lewis, R. E. et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer, 2003, 98, p. 292–299.

21. Singh, N., Limaye, A. P., Forrest, G. et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation, 2006, 81, p. 320–326.

22. Patterson, T. F., Boucher, H. W., Herbrecht, R. et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin. Infect. Dis., 2005, 41, p. 1448–1452.

23. Cordonnier, C., Bresnik, M., Ebrahimi, R. Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis. Mycoses, 2007, 50, p. 205–209.

24. Oppenheim, B. A., Herbrecht, R., Kusne, S. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin. Infect. Dis., 1995, 21, p. 1145–1153.

25. Denning, D. W., Ribaud, P., Milpied, N. et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis., 2002, 34, p. 563–571.

26. Perfect, J. R., Marr, K. A., Walsh, T. J. et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis., 2003, 36, p. 1122–1131.

27. Candoni, A., Mestroni, R., Damiani, D. et al. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Eur. J. Haematol., 2005, 75, p. 227–233.

28. Walsh, T. J., Raad, I., Patterson, T. F. et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis., 2007, 44, p. 2–12.

29. Maertens, J., Raad, I., Petrikkos, G. et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis., 2004, 39, p. 1563–1571.

30. Kartsonis, N. A., Saah, A. J., Joy Lipka, C. et al. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. Journal of Infection, 2005, 50, p. 196–205.

31. Aliff, T. B., Maslak, P. G., Jurcic, J. G. et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer, 2003, 97, p. 1025–1032.

32. Maertens, J., Glasmacher, A., Herbrecht, R. et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer, 2006, 107, p. 2888–2897.

33. Marr, K. A., Boeckh, M., Carter, R. A. et al. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis., 2004, 39, p. 797–802.

34. Raad, I., Hachem, R., Jiang, H. Combination Salvage Therapy of Invasive Aspergillosis (IA) in Patients with Hematologic Malignancy (HM): Which Caspofungin-Containing Regimen? Program and abstracts of the 44th ICAAC 2007: M-624.

35. de Carpentier, J. P., Ramamurthy, L., Denning, D. W. et al. An algorithmic approach to aspergillus sinusitis. J. Laryngol. Otol., 1994, 108, p. 314–318.

36. Patterson, T. F., Kirkpatrick, W. R., White, M. et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore), 2000, 79, p. 250–260.

37. Schwartz, S., Ruhnke, M., Ribaud, P. et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood, 2005, 106, p. 2641–2645.

38. Sunita, M., Martino, R., Franquet, T. et al. Invasive pulmonary aspergillosis in patients with hematologic malignancies: survival and prognostic factors. Haematologica, 2002, 87, p. 528–534.

39. Dignani, M. C., Anaissie, E. J., Hester, J. P. et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia, 1997, 11, p. 1621–1630.

40. Cordonnier, C., Ribaud, P., Herbrecht, R. et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin. Infect. Dis., 2006, 42, p. 955–963.

41. Bernard, A., Caillot, D., Couaillier, J. F. et al. Surgical management of invasive pulmonary aspergillosis in neutropenic patients. Ann. Thorac. Surg., 1997, 64, p. 1441–1447.

42. Gossot, D., Validire, P., Vaillancourt, R. et al. Full thoracoscopic approach for surgical management of invasive pulmonary aspergillosis. Ann. Thorac. Surg., 2002, 73, p. 240–244.

43. Pagano, L., Ricci, P., Nosari, A. et al. Fatal haemoptysis in pulmonary filamentous mycosis: an underevaluated cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature. Gimema Infection Program (Gruppo Italiano Malattie Ematologiche dell’Adulto). Br. J. Haematol., 1995, 89, p. 500–505.

44. Steinbach, W. J., Benjamin, D. K. Jr., Kontoyiannis, D. P. et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin. Infect. Dis., 2004, 39, p. 192–198.

45. Denning, D. W., Radford, S. A., Oakley, K. L. et al. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J. Antimicrob. Chemother., 1997, 40, p. 401–414.

46. Lass-Florl, C., Kofler, G., Kropshofer, G. et al. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J. Antimicrob. Chemother., 1998, 42, p. 497–502.

47. Smith, J., Safdar, N., Knasinski, V. et al. Voriconazole therapeutic drug monitoring. Antimicrob. Agents. Chemother., 2006, 50, p. 1570–1572.

48. Theuretzbacher, U., Ihle, F., Derendorf, H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin. Pharmacokinet., 2006, 45, p. 649–663.

49. Glasmacher, A., Hahn, C., Leutner, C. et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses, 1999, 42, p. 443–451.

50. Pasqualotto, A. C., Shah, M., Wynn, R. et al. Voriconazole plasma monitoring. Arch. Dis. Child., 2008.

51. Pascual, A., Calandra, T., Bolay, S. et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis., 2008, 46, p. 201–211.

52. Trifilio, S., Pennick, G., Pi, J. et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer, 2007, 109, p. 1532–1535.

53. Dodds Ashley, E., Lewis, R., Lewis, J. et al. Pharmacology of Systemic Antifungal Agents; doi:10.1086/504492. Clinical Infectious Diseases 2006; 43: S28-S39.

54. Glasmacher, A., Prentice, A. Current experience with itraconazole in neutropenic patients: a concise overview of pharmacological properties and use in prophylactic and empirical antifungal therapy. Clinical Microbiology & Infection, 12, p. 84–90.

55. Pascual, A., Nieth, V., Calandra, T. et al. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob. Agents. Chemother., 2007, 51, p. 137–143.

56. Leenders, A. C., Daenen, S., Jansen, R. L. et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br. J. Haematol., 1998, 103, p. 205–212.

Anaesthesiology, Resuscitation and Inten Intensive Care Medicine
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account